Are you Dr. Undevia?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 107 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
901 W Wellington Ave
Chicago, IL 60657Phone+1 773-296-5397Fax+1 773-296-7731- Is this information wrong?
Summary
- Dr. Samir Undevia, MD is a hematologist in Chicago, Illinois. He is currently licensed to practice medicine in Illinois. He is affiliated with University of Chicago Medical Center and Edward Hospital.
Education & Training
- University of ChicagoFellowship, Hematology and Medical Oncology, 2001 - 2004
- University of ChicagoResidency, Internal Medicine, 1997 - 2000
- New York University School of MedicineClass of 1997
Certifications & Licensure
- IL State Medical License 1997 - 2026
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- West Suburban Living Magazine Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Super Doctor SuperDoctors.com
Clinical Trials
- Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2003 Dec 01
- Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients Start of enrollment: 2005 Aug 01
- Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients Start of enrollment: 2007 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 41 citationsResults of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcomaWarren Chow, Paul Frankel, Chris Ruel, Dejka M. Araujo, Mohammed M. Milhem, Scott H. Okuno, Lee Hartner, Samir D. Undevia, Arthur P. Staddon> ;Cancer. 2020 Jan 1
- 24 citationsPhase II randomised discontinuation trial of brivanib in patients with advanced solid tumoursRobin L. Jones, Mark J. Ratain, Peter J. O'Dwyer, Lillian L. Siu, Jacek Jassem, Jacques Medioni, Maja DeJonge, Charles M. Rudin, Michael B. Sawyer, David Khayat, Ahmad...> ;European Journal of Cancer. 2019 Oct 1
- Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM modelRashmi Chugh, Kent A. Griffith, Elizabeth J. Davis, Dafydd G. Thomas, J. D. Zavala, Gino Metko, Bruce Brockstein, Samir D. Undevia, Walter M. Stadler, Scott M. Schuetze> ;Annals of Oncology. 2019 Aug 1
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- University of Chicago Medical CenterChicago, Illinois
- Edward HospitalNaperville, Illinois